DOCSLIB.ORG

What a Rheumatologists Needs to Know About Nephrology

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
What a Rheumatologists Needs to Know About Nephrology What a Rheumatologists needs to know about Nephrology Dr Louise Moist University of Western Ontario Louise/[email protected] May 2014 Disclosures • Advisory board Amgen, Leo Pharma, Roche Learning Objectives • Update in recent trends in nephrology pertinent to the rheumatologists in: • Proteinuria/eGFR • Lupus nephritis • Gout in CKD • Pain control in CKD • Drugs in CKD 3 Kidney Disease 101 Damage Function – Microalbuminuria is – Measure Cr a marker of – Interpret with age, vascular/ sex, weight endothelial damage – eGFR – Microalbuminuria – If abnormal consider is a risk factor CVD other kidney function and CKD – Lytes, Ca, Phos, Hb,acid base, clearance (urea) Proteinuria predicts progression to ESRD > than Creatinine 100x > risk of Dialysis Rate per 1,000 Patient Years Patient per 1,000 Rate Hemmelgarn et.al. JAMA. 2010;303(5):423-429 Proteinuria predicts death >creatinine Almost 10X > risk Rate per 1,000 Patient Years Patient per 1,000 Rate Hemmelgarn et.al. JAMA. 2010;303(5):423-429 KEY POINT When you see this... High albumin to creatinine ratio Or proteinuria on dip stick Think this... HIGH CVD RISK GFR(mL/min/1.73m2) > 90 60-89 30-59 15-29 <15 Stage 1 2 3 4 5 Kidney Severe Failure Moderate GFR Kidney GFR damage Kidney with mild Description damage GFR with normal or GFR Endstage Kidney Disease (ESKD) = Dialysis or Transplantation Stages of CKD GFR Hypertension* Hemoglobin < 12.0 g/dL Unable to walk 1/4 mile Serum albumin < 3.5 g/dL Serum calcium < 8.5 mg/dL Serum phosphorus > 4.5 mg/dL 90 80 70 60 50 40 30 20 10 Proportion of population (%) of population Proportion 0 15-29 30-59 60-89 90+ Estimated GFR (ml/min/1.73 m2) *>140/90 or antihypertensive medication p-trend < 0.001 for each abnormality Abnormalities in Uremia “Uremia” & the Uremic Toxin Membrane permeability & Intracellular Ca2+ integrity PTH (9000 daltons) Protein catabolism Soft tissue calcification Alters/mitochondrial pathways/ ATP generation abN phospholipid turnover Brain Platelets Glucose Pancreas Myocardium intolerance When you see this... Creatinine 145 umol/L eGFR == 35ml/min consistent with stage 3 CKD Think this... HIGH CVD RISK Impaired Immunity Early CKD: altered cellular & humoral immunity Alterations in PMN leukocytes – CHO metab, ATP generation, endothelial cell adherance, ROS generation – Impaired chemotaxis, phagocytosis, intracellular bacterial killing Moderate lymphocytoepenia (circulating T cells) Interferon production Pt more susceptible to infections e.g. T.B., bacteremias, cancers, response to Hep B vaccinations Mortality: The Facts Stages 1-4 – Risk of death from CVD >>> renal disease – 40% of patients with CKD will have CVD related death – Approximately: Each 10 umol/L SCr • 39% mortality • 59% CVD related death • Normotensive patients with MI Mortality: Stage 5 Cardiac events in ESRD 3.5-50 times GP Annual mortality on dialysis 15-20% Cardiac causes of death 45% Post MI – 1 year mortality = 59% – 5 year mortality =90% CKD Management Reduce CKD progression – BP control – Regression of proteinuria – Use of ACEI/ARB – Smoking cessation Cardiovascular risk reduction – Depends on stage of CKD Nephrology vs Rheumatology • Experienced, dedicated, committed Dr. • Stage 4 CKD for sure • Management of CVS risk s • Comanagement Patient Subsets Population vs. Patient MS LN ( Lupus nephritis) 26 yo Creat 260 eGFR 30 (?),protein 2 g24 h, unwell Anti dna 800, rash, leukopenia, Biopsy Class IV LN Steroids MMF or Cyclophosphamide Common Mistakes in Treating Lupus 1. Assuming Cyclophosphamide is the gold standard Am J Kidney Dis. 63(4):667-676 2014 MMF vs CYC for LN-Results of the ALMS Trial Black, Hispanic, Hispanic, Black,Mixed •The ALMS trial did not achieve its primary endpoint •ALMS was NOT a non-inferiority trial •However MMF has increasingly become the SOC Appel, et al., JASN, 2009; Isenberg, et al, Rheumatol, 2010 MMF vs CYC for SEVERE LN Defined as LN presenting with renal insufficiency Rovin et al., CJASN, 2012 Common Mistakes in Treating Lupus 3. NOT USING ANTIMALARIAL AGENTS ROUTINELY • decrease the frequency of lupus flare • improves kidney outcomes • increased probability of remission in membranous nephritis treated with MMF when combined with hydroxychloroquine • lowers probability of decrease in kidney function if used prior to the onset of lupus nephritis • probability of receiving an antimalarial agent is only 50% if their primary lupus physician is a nephrologist Am J Kidney Dis. 63(4):667-676 2014 Common Mistakes in Treating Lupus 4. USING URINARY SEDIMENT FOR RESPONSE CRITERIA • ACR recommends using urinary sediment for assessing response • improvement defined as changing from active urinary sediment to inactive urinary sediment (5 RBCs, 5 WBC, and noRBCs and no WBCs • the quantity of cells or casts is influenced by the duration of centrifuge time • mesangial proliferation (class II nephritis) can be associated with RBCs and casts and these lesions do not require immunosuppressive • using urinary sediment for response criteria can be misleading and result in unnecessary use of potentially toxic therapies. Am J Kidney Dis. 63(4):667-676 2014 Common Mistakes in Treating Lupus NOT REDUCING OR MINIMIZING IMMUNOSUPPRESSIVE EXPOSURE IN PATIENTS WITH ADVANCED KIDNEY DISEASE • CKD 4 or 5 D , a renal-limited flare might not warrant immunosuppressive tx • significant scarring in the kidney • very little or no benefit from another course of therapy. • immunotherapy guided by extrarenal manifestations. • dialysis pt immunosuppressive dose should be minimized high risk of infection. Am J Kidney Dis. 63(4):667-676 Common Mistakes in Treating Lupus WHEN to do A BIOPSY • Abnormal renal function • Careful in young people Creat 50 increases to 90 • Proteinurea • 1 gram may be masked if on ACEI ARB • Consider if marked change in presentation • Fibrosis scarring vs active disease • Risk vs Benefit Case -Clinical History 51 y.o. female SLE presented with microscopic hematuria creatinine 80 to 115 mol/L over 2 years • Positive ANA (1:640) with anti-Smith antibodies • C3 level low normal C4 level • UA: large blood, 1+ protein, and 20 RBCs/ HPF, • Urine protein-creatinine ratio was 0.5 • positive lupus anticoagulant What additional information would you like? MS LN ( Lupus nephritis) 6 months later MMF 1250 gm bid prednisone 15mg ,ramipril 5mg, Plaquenil Creat 120 eGFR 60 ,protein .5g24 h • 2mo later returns creat 190, alb/cr 50 Lupus nephritis Rule out other causes of rise in creatinine • Volume status • Drugs NSIADs, ACEI, ARB,DRI • Predisone ( urea) • Septra • ACEi ARB DRI Repeat Cr follow up Lupus nephritis Pregnancy • Education risks • Remission 6mo • Lupus anticoaulant before BCP • Switch to azothioprine and stable • Off ramipril • Stay on hydroxychloroqine • Prognosis based on renal function Cr 160 • Co manage high risk OB Gout in CKD MR Tophi 65 yo HT, Creat 162 eGFR 42ml/min Ramipril, HcT, ASA 81mg. Statin Boys weekend ( moose meat, booze) Acute gout, treated wih NSAID, 3 days later to emerg Creat 640 uric acid 800 Mr Tophi Cause of AKI? ACEI / NSAID combo dehydration Time to recovery • Renal mass Need for prophylaxis? dose of Allopurinol exacerbation of gout Gout in CKD Treatment Prevention • NSAIDS • Colchicine • 20% excreted kidneys • neuropathy, myopathy, BM • Colchicine • No if eGFR < 15ml • 1-2 0.6mg per day • 15-30 ml q 3days • Caution statins • Allopurinol • Steroids • Dose reductions? • Slow titration • Uloric • No role for uricosurics < 60ml Drugs In CKD and Rheumatology Victim Accessory Gentamycin Disruption of Functions Acyclovir NSAIDs Indinavir Thiazide diuretics Sodium phosphate TMP-SMX Pamidronate Cisplatin Prolonged Effects Hetastarch Benzodiazapines Calcineurin inhibitors Methotrexate Gold Glyburide NSAIDs Beta-lactams Drug Use in CKD Drug use in CKD Septra and CKD Dose-response • SS TMP-SMX, OR = 3.4 (1.6 – 7.4) • DS TMP-SMX, OR = 6.6 (3.5 – 12.6) Hyperkalemia • 14% of patients had electrolyte testing after Rx • Absolute risk of hyperkalemia = 6.9/1000 TMP-SMX Rx Mortality • 26/189 (14%) died during admission • Absolute risk of death (21 day) = 26.2/1000 TMP-SMX Rx Slide courtesy of Matt Weir Pain Control and CKD . Modified WHO analgesic ladder in patients with chronic kidney Parmar MS, Parmar KS. 2013 [v3; ref status: indexed, http://f1000r.es/10f] F1000Research 2013, 2:28 (doi: 10.12688/f1000research.2-28.v3) Pain Control in CKD Metabolic Bone DiseASE Renal Osteodystrophy Diagnosis of Osteoporosis in CKD • hip fracture risk women > 65 • eGFR of 45 to 59 mL/minute (HR 1.57, 95% CI 0.89-2.76) • eGFR <45 mL/minute (HR 2.32, 95% CI 1.15-4.68) • FRAX no eGFR • DXA measures areal BMD, rather than volumetric BMD • cannot distinguish cortical and trabecular bone • cannot assess bone microarchitecture/ bone turnover • DXA eGFR > 30 hyperparathyroidism, hyperPO4 • Oral bisphosphonate • DXA <30 is not routinely performed • Only under special circumsances Summary • CKD secondary to factors related to Rheum is multifactorial and multidisciplinaery • Each stage has associated multi-system morbidities • Management of the Rheum Dx • Prevent progression with aggressive BP and proteinuria control • Prevent CVD using CKD specific risk factor modification Thank You! .
Load more

Recommended publications
  • Rheumatology?
    WHAT IS RHEUMATOLOGY? diseases affect nearly 50 million Americans and can cause joint and organ destruction, severe pain, disability and even death. Inflammatory rheumatic diseases with arthritis cause more disability in America than heart disease, cancer or diabetes. How can a Rheumatologist help? Most rheumatologic conditions previously led to severe disability and even death in many patients. Evidence-based medical treatment of rheumatological disorders is currently helping patients with rheumatism lead a near-normal life. Medications such as Methotrexate and Tumor necrosis factor inhibitors have had a significant impact on patients with Rheumatoid Arthritis (RA), and today patients with RA can lead a pain free and productive life. Rheumatology facts by numbers: • Over 7 million American adults suffer from inflam- matory rheumatic diseases; 1.3 million adults have rheumatoid arthritis; and 161,000 to 322,000 adults have lupus. • 8.4 percent of women will develop a rheumatic dis- heumatology is a rapidly ease during their lifetime. Women are 2 to 3 times R evolving subspecialty in more likely to be diagnosed with RA, and 10 times internal medicine and more likely to develop lupus than men. pediatrics which includes the pathogenesis, diagnosis, and • 5 percent of men in the U.S. will develop a rheu- management of over 100 complex inflammatory and matic disease during their lifetime. connective tissue diseases. Rheumatologists care for a wide • Osteoporosis and low bone mass are currently esti- array of patients – from children to senior citizens, see mated to be a major public health threat for almost diseases like Rheumatoid Arthritis, Systemic Lupus 44 million U.S.
    [Show full text]
  • 2017 American College of Rheumatology/American Association
    Arthritis Care & Research Vol. 69, No. 8, August 2017, pp 1111–1124 DOI 10.1002/acr.23274 VC 2017, American College of Rheumatology SPECIAL ARTICLE 2017 American College of Rheumatology/ American Association of Hip and Knee Surgeons Guideline for the Perioperative Management of Antirheumatic Medication in Patients With Rheumatic Diseases Undergoing Elective Total Hip or Total Knee Arthroplasty SUSAN M. GOODMAN,1 BRYAN SPRINGER,2 GORDON GUYATT,3 MATTHEW P. ABDEL,4 VINOD DASA,5 MICHAEL GEORGE,6 ORA GEWURZ-SINGER,7 JON T. GILES,8 BEVERLY JOHNSON,9 STEVE LEE,10 LISA A. MANDL,1 MICHAEL A. MONT,11 PETER SCULCO,1 SCOTT SPORER,12 LOUIS STRYKER,13 MARAT TURGUNBAEV,14 BARRY BRAUSE,1 ANTONIA F. CHEN,15 JEREMY GILILLAND,16 MARK GOODMAN,17 ARLENE HURLEY-ROSENBLATT,18 KYRIAKOS KIROU,1 ELENA LOSINA,19 RONALD MacKENZIE,1 KALEB MICHAUD,20 TED MIKULS,21 LINDA RUSSELL,1 22 14 23 17 ALEXANDER SAH, AMY S. MILLER, JASVINDER A. SINGH, AND ADOLPH YATES Guidelines and recommendations developed and/or endorsed by the American College of Rheumatology (ACR) are intended to provide guidance for particular patterns of practice and not to dictate the care of a particular patient. The ACR considers adherence to the recommendations within this guideline to be volun- tary, with the ultimate determination regarding their application to be made by the physician in light of each patient’s individual circumstances. Guidelines and recommendations are intended to promote benefi- cial or desirable outcomes but cannot guarantee any specific outcome. Guidelines and recommendations developed and endorsed by the ACR are subject to periodic revision as warranted by the evolution of medi- cal knowledge, technology, and practice.
    [Show full text]
  • Rheuma.Stamp Line&Box
    Arthritis Mutilans: A Report from the GRAPPA 2012 Annual Meeting Vinod Chandran, Dafna D. Gladman, Philip S. Helliwell, and Björn Gudbjörnsson ABSTRACT. Arthritis mutilans is often described as the most severe form of psoriatic arthritis. However, a widely agreed on definition of the disease has not been developed. At the 2012 annual meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA), members hoped to agree on a definition of arthritis mutilans and thus facilitate clinical and molecular epidemiological research into the disease. Members discussed the clinical features of arthritis mutilans and defini- tions used by researchers to date; reviewed data from the ClASsification for Psoriatic ARthritis study, the Nordic psoriatic arthritis mutilans study, and the results of a premeeting survey; and participated in breakout group discussions. Through this exercise, GRAPPA members developed a broad consensus on the features of arthritis mutilans, which will help us develop a GRAPPA-endorsed definition of arthritis mutilans. (J Rheumatol 2013;40:1419–22; doi:10.3899/ jrheum.130453) Key Indexing Terms: OSTEOLYSIS ANKYLOSIS PENCIL-IN-CUP SUBLUXATION FLAIL JOINT ARTHRITIS MUTILANS Psoriatic arthritis (PsA) is an inflammatory musculoskeletal gists as a severe destructive form of PsA, a precise disease specifically associated with psoriasis. Moll and definition has not yet been universally accepted. The earliest Wright defined PsA as “psoriasis associated with inflam- definition of arthritis mutilans was provided
    [Show full text]
  • Rheumatology Connections
    IN THIS ISSUE Uncommon Manifestations of SLE 3 | PACNS or RCVS? 6 | Psychosocial Burden of PsA 9 Advances in IL-6 Biology 10 | AHCT for Systemic Sclerosis 12 | PET in Large Vessel Vasculitis 14 Rheumatology Connections An Update for Physicians | Summer 2018 112236_CCFBCH_18RHE1077_ACG.indd 1 7/10/18 2:06 PM Dear Colleagues, Welcome to another issue of Rheumatology Con- From the Chair of Rheumatic nections. I think you’ll find our title perfectly apt as and Immunologic Diseases you browse these articles, full of connections to an array of other specialties, to our patients and to our clinical, scientific and educational missions. Dr. Chatterjee’s collaboration with the Department of Medical Oncology and Hematology for treating severe systemic sclerosis is but one example of the relevance of our field across disciplines (p. 12). Cleveland Clinic’s Rheumatology This issue also features a study of psychosocial fac- Program is ranked among the top tors in psoriatic arthritis co-authored by Dr. Husni 2 in the nation in U.S. News & and a colleague in the Neurological Institute (p. 9). World Report’s “America’s Best Our connections to neurology become even clearer Hospitals” survey. as Drs. Calabrese and Hajj-Ali offer guidance on distinguishing between a neurological condition and the more fatal, less common rheumatologic one that it mimics (p. 6). Rheumatology Connections, published by We are always searching for ways to transcend Cleveland Clinic’s Department of Rheumatic disciplinary boundaries to provide better patient care. Our multidisciplinary style of caring for patients was and Immunologic Diseases, provides information critical in a case co-authored with a colleague in pathology and Drs.
    [Show full text]
  • Rheumatology Certification Exam Blueprint
    Rheumatology Certification Examination Blueprint Purpose of the exam The exam is designed to evaluate the knowledge, diagnostic reasoning, and clinical judgment skills expected of the certified rheumatologist in the broad domain of the discipline. The ability to make appropriate diagnostic and management decisions that have important consequences for patients will be assessed. The exam may require recognition of common as well as rare clinical problems for which patients may consult a certified rheumatologist. Exam content Exam content is determined by a pre-established blueprint, or table of specifications. The blueprint is developed by ABIM and is reviewed annually and updated as needed for currency. Trainees, training program directors, and certified practitioners in the discipline are surveyed periodically to provide feedback and inform the blueprinting process. The primary medical content categories of the blueprint are shown below, with the percentage assigned to each for a typical exam: Medical Content Category % of Exam Basic and Clinical Sciences 7% Crystal-induced Arthropathies 5% Infections and Related Arthritides 6% Metabolic Bone Disease 5.5% Osteoarthritis and Related Disorders 5% Rheumatoid Arthritis 13% Seronegative Spondyloarthropathies 6.5% Other Rheumatic and Connective Tissue Disorders (ORCT) 16.5 % Lupus Erythematosus 9% Nonarticular and Regional Musculoskeletal Disorders 7% Nonrheumatic Systemic Disorders 9% Vasculitides 8.5% Miscellaneous Topics 2% 100% Exam questions in the content areas above may also address clinical topics in geriatrics, pediatrics, pharmacology and topics in general internal medicine that are important to the practice of rheumatology. Exam format The exam is composed of multiple-choice questions with a single best answer, predominantly describing clinical scenarios.
    [Show full text]
  • Use of Diagnostic Imaging in Rheumatology Practice
    AMERICAN COLLEGE OF RHEUMATOLOGY POSITION STATEMENT SUBJECT: Use of diagnostic imaging in rheumatology practice PRESENTED BY: Committee on Rheumatologic Care FOR DISTRIBUTION TO: Members of the American College of Rheumatology Medical Societies Members of Congress Health Care Organizations/Third Party Carriers Managed Care Entities POSITION: 1. The American College of Rheumatology supports the ordering, performance and/or interpretation of imaging studies of the musculoskeletal system as an integral part of the rheumatology practice. A rheumatologist’s unique training in the clinical diagnosis and management of rheumatic diseases, as well as demonstrated abilities and competence in diagnostic imaging, combine to increase the relevance of imaging studies performed or interpreted by a rheumatologist which can be better tailored to an individual patient’s problem(s). 2. The ACR further supports the propriety of the assessment and collection of appropriate fees for these services. The ACR supports reimbursement by Medicare and other insurers for the performance and interpretation of musculoskeletal imaging studies and bone mineral density measurements by rheumatologists. BACKGROUND: Rheumatologists routinely evaluate, diagnose and manage patients with arthritis, systemic rheumatic, autoimmune, autoinflammatory syndromes, osteoporosis and metabolic bone disease as well as other disorders of connective tissues, muscles, bones and joints. Diagnostic and interventional imaging of the musculoskeletal system provide rheumatologists with information critical to the diagnosis, evaluation of damage, and progression or halting of progression of arthritic diseases (1-3). Specifically regarding conventional radiographs, rheumatologists, unlike radiologists, have the ability to assess erosive changes in the context of other disease activity measures and clinically relevant information, allowing for more robust treatment decision-making (4).
    [Show full text]
  • Prevalence and Impact of Reported Drug Allergies Among Rheumatology Patients
    diagnostics Article Prevalence and Impact of Reported Drug Allergies among Rheumatology Patients Shirley Chiu Wai Chan , Winnie Wan Yin Yeung, Jane Chi Yan Wong, Ernest Sing Hong Chui, Matthew Shing Him Lee, Ho Yin Chung, Tommy Tsang Cheung, Chak Sing Lau and Philip Hei Li * Division of Rheumatology and Clinical Immunology, Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Pokfulam, Hong Kong; [email protected] (S.C.W.C.); [email protected] (W.W.Y.Y.); [email protected] (J.C.Y.W.); [email protected] (E.S.H.C.); [email protected] (M.S.H.L.); [email protected] (H.Y.C.); [email protected] (T.T.C.); [email protected] (C.S.L.) * Correspondence: [email protected]; Tel.: +852-2255-3348 Received: 28 October 2020; Accepted: 7 November 2020; Published: 9 November 2020 Abstract: Background: Drug allergies (DA) are immunologically mediated adverse drug reactions and their manifestations depend on a variety of drug- and patient-specific factors. The dysregulated immune system underpinning rheumatological diseases may also lead to an increase in hypersensitivity reactions, including DA. The higher prevalence of reported DA, especially anti-microbials, also restricts the medication repertoire for these already immunocompromised patients. However, few studies have examined the prevalence and impact of reported DA in this group of patients. Methods: Patients with a diagnosis of rheumatoid arthritis (RA), spondyloarthritis (SpA), or systemic lupus erythematosus (SLE) were recruited from the rheumatology clinics in a tertiary referral hospital between 2018 and 2019. Prevalence and clinical outcomes of reported DA among different rheumatological diseases were calculated and compared to a cohort of hospitalized non-rheumatology patients within the same period.
    [Show full text]
  • Co-Existent Sickle Cell Disease and Juvenile Rheumatoid Arthritis. Two Cases with Delayed Diagnosis and Severe Destructive Arthropathy
    Case Report Co-existent Sickle Cell Disease and Juvenile Rheumatoid Arthritis. Two Cases with Delayed Diagnosis and Severe Destructive Arthropathy KIRAN NISTALA and KEVIN J. MURRAY ABSTRACT. We describe 2 pediatric patients with sickle cell disease (SCD) who developed seropositive juvenile rheumatoid arthritis (JRA). Both patients have severe joint damage, the compound effect of both disease processes. The bone and cartilage destruction, which poses serious therapeutic challenges, highlights the difficulty of making a diagnosis of chronic inflammatory disease in the setting of SCD. There may be a correlation between increased levels of tumor necrosis factor-α in the synovial tissue of joints damaged by arthritis and local sickling. The resultant ischemia and corresponding inflammatory infiltrates could in turn worsen existing synovial proliferation and cartilage destruc- tion as well as trigger further sickling. (J Rheumatol 2001;28:2125–8) Key Indexing Terms: JUVENILE RHEUMATOID ARTHRITIS SICKLE CELL ANEMIA TUMOR NECROSIS FACTOR There are several well recognized rheumatological manifes- CASE REPORT tations of sickle cell disease (SCD) including avascular Case 1. Patient 1, a 15-year-old girl, was diagnosed with SCD at the age of necrosis, dactylitis and septic arthritis. Synovial effusions 2 after presenting with pneumococcal meningitis associated with an acute vasoocclusive sickle crisis. Since that time she has continued to have about secondary to adjacent bone infarction occur in almost 20% 4 sickle cell crises per year, usually affecting the lumbar spine and chest. 1 of acute crises . However, true cases of rheumatic disorders At the age of 14, she developed recurrent pain and swelling of her left such as rheumatoid arthritis (RA) in association with SCD great toe.
    [Show full text]
  • Rheumatic Associations of Autoimmune Thyroid Disease: a Systematic Review
    Clinical Rheumatology (2019) 38:1801–1809 https://doi.org/10.1007/s10067-019-04498-1 REVIEW ARTICLE Rheumatic associations of autoimmune thyroid disease: a systematic review Clement E. Tagoe1,2 & Tejas Sheth3 & Eugeniya Golub1 & Karen Sorensen4 Received: 5 February 2019 /Revised: 22 February 2019 /Accepted: 27 February 2019 /Published online: 29 March 2019 # International League of Associations for Rheumatology (ILAR) 2019 Abstract To investigate specific disease patterns in the rheumatic manifestations associated with autoimmune thyroid disease (AITD) through a systematic literature review. We performed a systematic review using the Medline OVID, PubMed, EMBASE, and Web of Science databases through May 2018 for experimental and observational studies that explored the association of AITD with degenerative joint disease (DJD), osteoarthritis (OA), chronic widespread pain (CWP) and fibromyalgia syndrome (FMS), and seronegative inflammatory arthritis (IA). A total of 2132 articles were identified. After title and abstract screening and removal of duplicates, 66 articles were retrieved for full text review. Eighteen studies were deemed eligible for inclusion. Six observational studies reported up to 45% prevalence of DJD in AITD. Hand and spinal DJD were reportedly associated with higher odds of AITD. Twelve observational studies were retrieved reporting up to 62% prevalence of FMS in AITD patients. Four studies described the occurrence of seronegative IA in AITD patients. The rheumatic associations of AITD may manifest specific patterns of disease distinct from those of other well-defined autoimmune syndromes and contribute significantly to disease burden. Keywords Autoimmunethyroiddisease .Chronicwidespreadpain .Fibromyalgia .Hashimotothyroiditis .Osteoarthritis .Spinal degenerative disc disease Introduction proportion of patients with Graves’ disease may present with clinically significant hyperthyroidism and Graves’ The autoimmune thyroid diseases (AITD) comprise a spec- ophthalmopathy.
    [Show full text]
  • The Boston Weighted Criteria for the Classification of Systemic Lupus Erythematosus KAREN H
    Defining Lupus Cases for Clinical Studies: The Boston Weighted Criteria for the Classification of Systemic Lupus Erythematosus KAREN H. COSTENBADER, ELIZABETH W. KARLSON, MATTHEW H. LIANG, and LISA A. MANDL ABSTRACT. Objective. The 1982 American College of Rheumatology (ACR) revised criteria for the classifica- tion of systemic lupus erythematosus (SLE), updated in 1997, have become the standard for estab- lishing eligibility of subjects for epidemiologic and clinical lupus studies. These criteria may exclude patients with limited disease, restricting the generalizability of research findings. We developed and evaluated the ability of a weighted classification system to identify a broader spectrum of patients with lupus. Methods. We constructed the Boston Weighted Criteria system for the classification of SLE, updating that developed in 1984. Using a hospital billing database, we identified 27l patients seen in our rheumatology clinic for possible SLE and reviewed medical records for all ACR criteria and the treating rheumatologist’s diagnosis. We compared both the Boston Criteria and the treating rheuma- tologist’s diagnosis to the updated 1982 ACR criteria; we also compared the Boston Criteria to the treating rheumatologist’s diagnosis. Results. The Boston Criteria identified 190/271 patients as having SLE, the rheumatologist’s diag- nosis identified 179/271, and the ACR criteria identified 171/271. The Boston Criteria had a sensi- tivity of 93% and specificity of 69% compared to the ACR criteria, and would identify 7% more patients. Conclusion. The Boston Criteria identify a larger number of patients compared with the current ACR criteria, while retaining face validity. This reflects the inclusion of patients with objective find- ings of SLE but less than 4 ACR criteria.
    [Show full text]
  • Rheumatology: 3. Getting the Most out of Radiology Review Synthèse
    Clinical basics Rheumatology: 3. Getting the most out of radiology Review Synthèse From *†the Division of Rheumatology, Graham Reid,* John M. Esdaile† University of British Columbia, *†Vancouver The case General Hospital and A 72-year-old man has been seeing the same physician for 2 decades, and his †the Arthritis Research only complaint has been intermittent mild low-back pain over the last 8–10 Centre of Canada, years. The pain had not interfered with his enjoyment of an active life, which Vancouver, BC. included golf, tennis and gardening. However, over the past year the low- back pain has increased and is particularly noticeable when the man is walk- This article has been peer reviewed. ing. The pain radiates to his right thigh and calf. It is not aggravated by Val- salva’s manoeuvre and is relieved within 2 minutes by sitting. The man has CMAJ 2000;162(9):1318-25 had to give up most of his activities and can walk only 2 blocks. Over-the- counter analgesics and anti-inflammatory drugs, chiropractic, physiotherapy This series has been reviewed and massage have not provided lasting relief. His physician notices that he and endorsed by the Canadian walks with a slightly stooped posture. The examination, including a detailed Rheumatology Association. neurologic assessment, is normal except for tenderness over the L5–S1 verte- brae and quite marked restriction of lumbar spine movements. The Arthritis Society salutes CMAJ for its extensive series of articles on arthritis. The society believes or patients with musculoskeletal pain, imaging can aid in making or confirm- that this kind of information is ing a diagnosis.
    [Show full text]
  • PATIENT FACT SHEET Osteonecrosis
    PATIENT FACT SHEET Osteonecrosis Osteonecrosis is a painful condition that involves the Osteonecrosis usually occurs between the ages of 20 death of bone cells due to decreased blood flow. It is and 50 years. Bones and bone marrow need steady also called avascular necrosis (AVN) or aseptic necrosis. blood supply to stay healthy. Decreased blood flow It is a painful condition most commonly occurring in causes bone cells to die. Corticosteroid use, heavy the hips or knees, and is often more symptomatic with drinking, lupus and severe trauma or injury may cause CONDITION any weight-bearing activities, such as walking. In some osteonecrosis. cases, the bone at the hip (femoral head) may collapse. Rarer causes of osteonecrosis include HIV, DESCRIPTION Shoulders, hands and feet are less often affected. Rarely, decompression disease (“the bends”), blood disorders osteonecrosis affects the jaw (see separate chapter for such as sickle cell anemia, radiation therapy, and details on osteonecrosis of the jaw). organ transplant. An early sign of osteonecrosis is local pain in the Diagnosis of osteonecrosis begins with an x-ray of the affected bone or joint. Hip osteonecrosis may cause painful area. Other imaging tests such as bone scans or pain in the groin. Pain from hip or knee osteonecrosis magnetic resonance imaging (MRI) may be needed. MRI may be worse during weight-bearing or walking. Nearby is effective for early osteonecrosis detection, particularly joints may develop osteoarthritis. when the x-rays do not reveal change. SIGNS/ SYMPTOMS Treatment of early osteonecrosis includes pain collapse may need total joint replacement of the hip or medications and modifying activity to reduce weight- knee.
    [Show full text]